Questions: Receptor Types and Intracellular Signaling

Question 1

A newly discovered receptor binds glutamate (normally an excitatory neurotransmitter) but gates Cl⁻ channels. What effect would activating this receptor have on the postsynaptic neuron?

• A. Excitatory — glutamate is the brain's primary excitatory neurotransmitter
• B. Inhibitory — Cl⁻ influx hyperpolarizes the membrane regardless of which neurotransmitter opens the channel
• C. No effect — ionotropic receptors for glutamate cannot gate anions
• D. Excitatory — Cl⁻ influx always depolarizes neurons

Answer: (B)

The effect of a neurotransmitter depends entirely on which ions the receptor gates, not on the identity of the neurotransmitter. Cl⁻ influx raises the negative charge inside the cell, hyperpolarizing the membrane and making it harder to fire — that is inhibition, regardless of what opened the channel. Option A embodies the classic misconception: glutamate is typically excitatory because its receptors (AMPA, NMDA) gate Na⁺ and Ca²⁺, not because glutamate itself is inherently excitatory.

Question 2

A drug produces slow, prolonged inhibition by activating K⁺ channels indirectly through a second-messenger cascade. Which receptor type is most likely involved?

• A. Ionotropic, because K⁺ channels are voltage-gated
• B. Metabotropic, because indirect activation via second messengers is a defining feature of GPCRs
• C. Ionotropic, because all inhibitory signals require fast Cl⁻ influx
• D. Metabotropic, but only if the second messenger is cAMP specifically

Answer: (B)

Metabotropic (G-protein-coupled) receptors work through intracellular second-messenger cascades and produce slow, prolonged effects lasting seconds to minutes. Indirect activation of K⁺ channels via G-protein signaling is a classic metabotropic mechanism (as in GABA-B receptor signaling). Ionotropic receptors directly gate ion channels upon ligand binding — fast and transient. Option D is wrong because multiple second messengers (cAMP, DAG, IP3, etc.) can mediate metabotropic signaling.

Question 3

Metabotropic receptor signaling can produce effects that are more powerful than ionotropic signaling, even though it operates more slowly.

• T. True
• F. False

Answer: True

Although metabotropic signaling is slower (seconds to minutes vs. milliseconds), it is amplifying: one activated receptor can activate dozens of G-proteins, each activating multiple effector enzymes, each producing many second-messenger molecules. This cascade amplification means a small neurotransmitter signal can trigger a large cellular response. The misconception is equating 'slow' with 'weak' — metabotropic pathways can profoundly alter neuronal function, gene expression, and synaptic strength.

Question 4

Because GABA is the brain's main inhibitory neurotransmitter, most GABA receptors produce inhibition through the same mechanism.

• T. True
• F. False

Answer: False

GABA produces inhibition at both its receptor types but through fundamentally different mechanisms. GABA-A is ionotropic: ligand binding directly opens Cl⁻ channels, producing fast hyperpolarization in milliseconds. GABA-B is metabotropic: it works via G-proteins to open K⁺ channels and inhibit adenylyl cyclase, producing slower, more prolonged inhibition. Same neurotransmitter, same net direction (inhibitory), but entirely different receptor types, mechanisms, timescales, and pharmacological targets.

Question 5

Why does the pharmacological specificity of a drug depend on which receptor subtype it targets rather than simply which neurotransmitter system it affects?

Model answer: Because the same neurotransmitter can activate multiple receptor subtypes with different signal transduction mechanisms, timescales, and downstream effects. A drug targeting only one receptor subtype selectively alters one component of a neurotransmitter's effects while leaving others intact.

For example, dopamine acts on D1 receptors (stimulate cAMP, generally excitatory effects) and D2 receptors (inhibit cAMP, generally dampening effects). An antipsychotic that blocks D2 specifically can reduce excess dopaminergic signaling in circuits linked to psychosis without disrupting all dopaminergic function. If the drug simply 'blocked dopamine,' it would indiscriminately affect all receptor subtypes — causing far more side effects. Receptor-type specificity is what makes modern neuropharmacology possible.